Finance

Lists
NCYT:LON
Novacyt SA
GBX ३९.५०
-०.२५%
(-०.१००) 1D
अक्टोबर १६, १६:३५:२५ GMT+१  ·   GBX
All symbols
SymbolPriceChange% Change
Generating top insights for NCYT...
Open
GBX ३९.६०
High
GBX ३९.६८
Low
GBX ३९.२०
Mkt. cap
३.२४ करोड
Avg. vol.
१.०३ लाख
Volume
१२.२२ हजार
52-wk high
GBX ८६.००
52-wk low
GBX २६.६०
Shares outstanding
३.७७ करोड
No. of employees
२२८
Open
GBX ३९.६०
High
GBX ३९.६८
Low
GBX ३९.२०
Mkt. cap
३.२४ करोड
Avg. vol.
१.०३ लाख
Volume
१२.२२ हजार
52-wk high
GBX ८६.००
52-wk low
GBX २६.६०
Shares outstanding
३.७७ करोड
No. of employees
२२८
News stories
From web sources and news partners
Profile
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare. In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
About Novacyt SA
CEODavid Allmond
Employees२२८
Founded२००६ जुलाई ३
Headquarters-
Sector-
Previous reportsAll values in GBP
Loading Previous Earnings...
Revenue
Net income
All values in GBP
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
५१.१८ लाख
५१.१८ लाख
५७.७८ लाख
५७.७८ लाख
Cost of goods sold
२६.१४ लाख
२६.१४ लाख
२५.६० लाख
२५.६० लाख
Cost of revenue
२६.१४ लाख
२६.१४ लाख
२५.६० लाख
२५.६० लाख
Research and development expenses
१०.३४ लाख
१०.३४ लाख
१०.५८ लाख
१०.५८ लाख
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
४६.८८ लाख
४६.८८ लाख
४६.४९ लाख
४६.४९ लाख
Operating expense
५५.४२ लाख
५५.४२ लाख
५६.६३ लाख
५६.६३ लाख
Total operating expenses
८१.५६ लाख
८१.५६ लाख
८२.२२ लाख
८२.२२ लाख
Operating income
-३०.३८ लाख
-३०.३८ लाख
-२४.४४ लाख
-२४.४४ लाख
Other non operating income
-२३.०० हजार
-२३.०० हजार
-४७.५० हजार
-४७.५० हजार
EBT including unusual items
-१.०२ करोड
-१.०२ करोड
-२९.०६ लाख
-२९.०६ लाख
EBT excluding unusual items
-२५.१८ लाख
-२५.१८ लाख
-२७.९८ लाख
-२७.९८ लाख
Income tax expense
-१८.१४ लाख
-१८.१४ लाख
-४९.५० हजार
-४९.५० हजार
Effective tax rate
१७.८५%
१७.८५%
१.७०%
१.७०%
Other operating expenses
-१.८० लाख
-१.८० लाख
-४४.०० हजार
-४४.०० हजार
Net income
-८२.७० लाख
-८२.७० लाख
-२८.९७ लाख
-२८.९७ लाख
Net profit margin
-१६१.६०%
-१६१.६०%
-५०.१३%
-५०.१३%
Earnings per share
-
-
-
-
Interest and investment income
१.४९ लाख
१.४९ लाख
६३.०० हजार
६३.०० हजार
Interest expense
-१.४६ लाख
-१.४६ लाख
-१.३९ लाख
-१.३९ लाख
Net interest expenses
३.०० हजार
३.०० हजार
-७६.०० हजार
-७६.०० हजार
Depreciation and amortization charges
-
-
-
-
EBITDA
३४.६३ लाख
३४.६३ लाख
-१८.८५ लाख
-१८.८५ लाख
Gain or loss from assets sale
-३.०० हजार
-३.०० हजार
८.०० हजार
८.०० हजार
AI content may include mistakes. Learn more
Google एपहरू